Potent Tumor Organoid Infiltration and Killing by PBMC Derived Effector Cells

Conclusions:

1. The manufacture of SUPLEXA cells from PBMCs generates a mixture of NK cells, CD 8 T cells, CD 56 NK like T cells, and gd T cells with potent patient derived cancer organoid killing activity.
2. The observed killing of both colorectal and lung cancer organoid models by SUPLEXA cells indicate the potential fo r broad tumor killing activity.
3. SUPLEXA cells represent a novel autologous cellular therapeutic for cancer that will betested in phase 1 clinical trial starting by February 2022.